Prosecution Insights
Last updated: April 19, 2026
Application No. 18/512,294

Micellar Mouthwash Composition

Non-Final OA §102§103§DP
Filed
Nov 17, 2023
Examiner
ROBERTS, LEZAH
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Colgate-Palmolive Company
OA Round
1 (Non-Final)
48%
Grant Probability
Moderate
1-2
OA Rounds
4y 4m
To Grant
85%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allow Rate
363 granted / 750 resolved
-11.6% vs TC avg
Strong +36% interview lift
Without
With
+36.4%
Interview Lift
resolved cases with interview
Typical timeline
4y 4m
Avg Prosecution
78 currently pending
Career history
828
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
49.2%
+9.2% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
16.0%
-24.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 750 resolved cases

Office Action

§102 §103 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Election/Restrictions Applicant's election with traverse of Group I in the reply filed on December 19, 2025 is acknowledged. The traversal is on the ground(s) that it is not a serious burden to search both groups. This is not found persuasive because Burden consists not only of specific searching of classes and subclasses, but also of searching multiple databases for foreign references and literature searches. Burden also resides in the examination of independent claim set for clarity, enablement and double patenting issues. Further, a reference that would anticipate the invention of one group would not necessarily anticipate or even make obvious another group. Finally, the consideration for patentability is different in each case. Thus, it would be an undue burden to examine all of the above inventions in one application and the restriction for examination purposes as indicated above is deemed proper. . The requirement is still deemed proper and is therefore made FINAL. Claims 1-21 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected Invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on December 19, 2025. Claims Claim Rejections - 35 USC § 102 - Anticipation The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-3, 11 and 15-16 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Mintel (already of record, 2011). Mintel discloses a mouthwash comprising water, sorbitol, caprylyl/capryl glucoside (alkyl glucoside), olaflur (amine fluoride) and sodium fluoride (Ingredients). The composition is free of anionic surfactants. Mintel anticipates the instant claims. Claim Rejections - 35 USC § 103 - Obviousness The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. 1) Claims 1-6, 11 and 15-16 are rejected under 35 U.S.C. 103 as being unpatentable over Mintel (already of record, 2011) in view of Li et al. (WO 2021263151, already of record). Mintel discloses a mouthwash comprising water, sorbitol, caprylyl/capryl glucoside (alkyl glucoside), olaflur (amine fluoride) and sodium fluoride (Ingredients). The composition is free of anionic surfactants. Mintel differs from the instant claims insofar as it does not disclose the amounts of each components. Li et al. disclose mouthwash compositions. The mouthwash comprises a nonionic surfactant and includes alkyl glucosides, such as capryl/caprylyl glucoside and coco glucoside (paragraph 0029). The nonionic surfactant comprises 0.1 to 2% and 0.2 to 0.4% by weight of the composition (paragraph 0030) (instant claims 5-6). Fluoride may be used in the composition and includes amine fluoride (e.g., N'-octadecyltrimethylendiamine- Ν,Ν,Ν'-tris(2-ethanol)-dihydrofluoride) (olaflur) (page 9, 1.48). Generally, it is prima facie obvious to select a known material for incorporation into a composition, based on its recognized suitability for its intended use. See MPEP 2144.07. It would have been obvious for one of ordinary skill in the art prior to filing the instant application to have used 0.1% to 2% caprylyl/capryl glucoside in the composition of Mintel because this is a suitable amount of nonionic surfactant used in a mouthwash composition. It is obvious to replace one component for another equivalent component if it is recognized in the art that two components are equivalent and is not based on the Applicant disclosure. See MPEP 2144.06. It would have been obvious to one of skill in the art prior to the time the Application was filed to have used coco glucoside in place of caprylyl/capryl glucoside in the compositions of Mintel because they are taught as equivalents, as disclosed by Li et al. The amount of nonionic surfactant controls the clarity of the mouthwash. When lower amounts of glucoside surfactants are used, they create a cloudy composition. One of ordinary skill in the art would reasonably conclude that the composition would comprise micelles when low amounts of glucoside surfactant are used. 2) Claims 1-5, 11-13 and 15-16 are rejected under 35 U.S.C. 103 as being unpatentable over Mintel (already of record, 2011) in view of Poth (US 2021/0169757). Mintel discloses a mouthwash comprising water, sorbitol, caprylyl/capryl glucoside (alkyl glucoside), olaflur (amine fluoride) and sodium fluoride (Ingredients). The composition is free of anionic surfactants. Mintel differs from the instant claims insofar as it does not disclose the amounts of each components. Poth discloses stable oral care compositions comprising one or more alkyl glucosides (Abstract). Alkyl glucoside may be C.sub.8-25 alkyl glucoside, such as, C.sub.8-18 alkyl glucoside or C.sub.10-18 alkyl glucoside. These include lauryl glucoside and coco glucoside. In some embodiments, the alkyl glucoside may be present in an amount of from 2% to 3%, from 2.2% to 2.8%, from 2.4% to 2.6%, or about 2.5% by weight of the composition (paragraph 0084). The composition may comprise amine fluoride. The amine fluoride comprises greater than 0 to 0.8 wt% of the composition. The fluoride ion sources may be present in an amount sufficient to supply 25 ppm to 5,000 ppm of fluoride ions (paragraph 0088). The composition comprises water, optionally wherein water is present in an amount of from 10% to 80%. The composition may be formulated into a mouthwash (paragraph 0077). The composition does not comprises sodium lauryl sulfate and is free of anionic surfactants. Generally, it is prima facie obvious to select a known material for incorporation into a composition, based on its recognized suitability for its intended use. See MPEP 2144.07. It would have been obvious for one of ordinary skill in the art prior to filing the instant application to have used 2% alkyl glucoside and 0 to 0.8% amine fluoride in the composition of Mintel because these are suitable amounts of nonionic surfactant and amine fluoride used in a mouthwash composition. It is obvious to replace one component for another equivalent component if it is recognized in the art that two components are equivalent and is not based on the Applicant disclosure. See MPEP 2144.06. It would have been obvious to one of skill in the art prior to the time the Application was filed to have used coco glucoside in place of caprylyl/capryl glucoside in the compositions of Mintel because they are taught as equivalents, as disclosed by Poth et al. In regards to the amounts, in the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art”, a prima facie case of obviousness exists. MPEP 2144.05 A. The amounts of the combination of references, 2 to 3% alky glucoside and 0 to 0.8% amine fluoride, overlap that of the instant claims, 0.1% to 2.5% alkyl glucoside and 0.5% to 1.5% amine fluoride. Therefore, since an overlap exists here, the claims are obvious over the combination of references. 3) Claims 1-16 are rejected under 35 U.S.C. 103 as being unpatentable over Mintel (already of record, 2011) in view of Hug et al. (WO 2014094900). Mintel discloses a mouthwash comprising water, sorbitol, caprylyl/capryl glucoside (alkyl glucoside), olaflur (amine fluoride) and sodium fluoride (Ingredients). The composition is free of anionic surfactants. Mintel differs from the instant claims insofar as it does not disclose that the amine fluoride is made in situ or the amounts of the amine fluoride or nonionic surfactant (alkyl glucoside). Hug et al. disclose oral care composition comprising an amine fluoride. The amine fluoride may be added already formed or may be formed in situ when an amine base and fluoride are in solution together (paragraph 0086). The amine fluoride comprises at least one of Olaflur (paragraph 0030). The amine fluoride comprises 0.01 to 10 wt% of the composition (paragraph 0013). The compositions may comprise surfactants, including nonionic surfactants, and comprise 0 to 2 wt% based on the weight of the composition (paragraph 0015). Generally, it is prima facie obvious to select a known material for incorporation into a composition, based on its recognized suitability for its intended use. See MPEP 2144.07. It would have been obvious for one of ordinary skill in the art prior to filing the instant application to have formed the amine fluoride in situ by adding a fluoride salt and an amine base to the composition of Mintel because this is a method used in the art to incorporate amine fluoride in an oral care composition. It would have been obvious for one of ordinary skill in the art prior to filing the instant application to have used 0 to 2% caprylyl/capryl glucoside and 0.01 to 10 wt% amine fluoride in the composition of Mintel because they are suitable amounts for oral care compositions. The preferred amine fluoride is olaflur which a has an amine of claim 11. Therefore it would have been obvious to one of ordinary skill in the art to have used the amine base to make the amine fluoride of the Mintel because it would result in the formation of olaflur. In regards to the amounts, in the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art”, a prima facie case of obviousness exists. MPEP 2144.05 A. The amounts of the combination of references, 0 to 2% nonionic surfactant (alkyl glucoside) and 0.01 to 10% amine fluoride, overlap and encompass that of the instant claims, 0.1% to 2.5% alkyl glucoside and 0.5% to 1.5% amine fluoride, respectively. Therefore, since an overlap exists here, the claims are obvious over the combination of references. Claims 1-16 are rejected. Claims 19-21 are withdrawn. No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LEZAH ROBERTS whose telephone number is (571)272-1071. The examiner can normally be reached Monday-Friday 11:00-7:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached at 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LEZAH ROBERTS/ Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Nov 17, 2023
Application Filed
Jan 09, 2026
Non-Final Rejection — §102, §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594229
Personal Care Compositions and Methods for the Same
2y 5m to grant Granted Apr 07, 2026
Patent 12594241
TOPIRAMATE ORAL LIQUID SUSPENSION AND USE THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12582583
ORAL CARE PRODUCT COMPRISING AN ORAL CARE RHEOLOGICAL SOLID COMPOSITION
2y 5m to grant Granted Mar 24, 2026
Patent 12558387
MULTI-VIRUS ANTI-INFECTIVITY AND PRO-IMMUNITY ASSEMBLY
2y 5m to grant Granted Feb 24, 2026
Patent 12551417
STABILIZED STANNOUS COMPOSITIONS
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
48%
Grant Probability
85%
With Interview (+36.4%)
4y 4m
Median Time to Grant
Low
PTA Risk
Based on 750 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month